Sort
30,917 grants matching “tumor microenvironment”
MetaboCore: Needle biopsy assay of drug sensitivity for solid tumors.
$401,113Raymond Yeung · University Of Washington · U01 · FY2024 · CA
Study of the IL-33-driven immune cell organization underpinning responses to immune checkpoint blockade cancer therapy
$401,113Binfeng Lu · Hackensack University Medical Center · R01 · FY2025 · CA
Implantable microdevices with integrated optical imaging for high-throughput in situ tumor response and drug sensitivity measurement
$401,059Oliver Jonas · Brigham And Women'S Hospital · R37 · FY2018 · CA
Transcriptional Regulation of Dormancy and Emergence in Breast Cancer
$401,019Partha Roy · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · CA
Pathophysiologic Consequences of Neurotrophin Activation of Trk in Neuroblastoma
$400,991Carol Thiele-Galetto · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Collaborative Innate-Adaptive Immune Regulation of Tumor Progression
$400,975Matthew F Krummel · University Of California, San Francisco · U01 · FY2009 · CA
Brain Tumor Immunotherapy
$400,968Mark Gilbert · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Distinct Tumor and Metastatic Collagen Microenvironments: Divergent Targeting Approaches
$400,962Keith Syson Chan · Methodist Hospital Research Institute · R01 · FY2023 · CA
Analyzing Adhesion and Signaling Functions for PTPN12 in Invasive Glioma Cells
$400,950Joseph H McCarty · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · NS
Analyzing Adhesion and Signaling Functions for PTPN12 in Invasive Glioma Cells
$400,950Joseph H McCarty · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · NS
High-Parameter Cytometry Shared Resource
$400,938Christine Beeton · Baylor College Of Medicine · P30 · FY2020 · CA
Exploiting Caveolae-Dependent Albumin Endocytosis to Optimize Therapy in Pancreatic Cancer
$400,902Terence Marques Williams · Ohio State University · R01 · FY2016 · CA
Microbiome-Mediated Tumor Immunomodulation in a Pathomimetic Colorectal Cancer Chip
$400,890Hyun Jung Kim · Cleveland Clinic Lerner Com-Cwru · R33 · FY2025 · CA
Shifting the balance between IFN-I and TGF-beta to improve cancer therapy
$400,890Mark W Jackson · Cleveland Clinic Lerner Com-Cwru · P01 · FY2022 · CA
Shifting the balance between IFN-I and TGF-beta to improve cancer therapy
$400,890Mark W Jackson · Cleveland Clinic Lerner Com-Cwru · P01 · FY2025 · CA
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors
$400,868Fumito Ito · University Of Southern California · R01 · FY2023 · CA
Emodin as a chemopreventive agent for breast cancer
$400,859Daping Fan · University Of South Carolina At Columbia · R01 · FY2021 · CA
Molecular mechanism by which Tim-3 induces T cell dysfunction and inhibits anti-t
$400,845Vijay K Kuchroo · Brigham And Women'S Hospital · P01 · FY2018 · AI
Developmental Funds
$400,844Edward Chu · Albert Einstein College Of Medicine · P30 · FY2024 · CA
Development of a Novel Armored CAR-T Immunotherapeutic for Pancreatic Cancer
$400,835Gary G. Altman · Cambium Oncology Llc · R44 · FY2025 · CA
Clinical Neuroimmunology of Vaccines in Brain Tumors
$400,801John H Sampson · Duke University · R01 · FY2021 · NS
NRG Oncology Annual BIQSFP Progress Reports
$400,777Norman Wolmark · Nrg Oncology Foundation, Inc. · U10 · FY2025 · CA
Project 1: Tumor Microenvironment Initiators of the Metastatic Cascade in High-Risk Prostate Cancer
$400,761Joshua Michael Lang · University Of Wisconsin-Madison · P50 · FY2025 · CA
Project 3
$400,742Pasi A Janne · Dana-Farber Cancer Inst · P50 · FY2022 · CA
Clinical Neuroimmunology of Vaccines in Brain Tumors
$400,733John H Sampson · Duke University · R01 · FY2022 · NS